MARKET

MCRB

MCRB

Seres Therapeutics Inc
NASDAQ
7.88
+0.83
+11.69%
Closed 17:30 05/12 EDT
OPEN
7.15
PREV CLOSE
7.06
HIGH
8.09
LOW
7.15
VOLUME
99.89K
TURNOVER
0
52 WEEK HIGH
30.60
52 WEEK LOW
6.64
MARKET CAP
68.81M
P/E (TTM)
0.8549
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MCRB last week (0505-0509)?
Weekly Report · 1d ago
This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Benzinga · 4d ago
Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga · 5d ago
Seres Therapeutics Cut to Neutral From Buy by Chardan Capital
Dow Jones · 5d ago
Seres Therapeutics Price Target Raised to $6.00/Share From $1.25 by Chardan Capital
Dow Jones · 5d ago
Chardan Capital Downgrades Seres Therapeutics to Neutral, Raises Price Target to $6
Benzinga · 5d ago
Buy Rating Maintained for Seres Therapeutics Amid Promising SER-155 Developments and Financial Stability
TipRanks · 5d ago
Seres Therapeutics downgraded to Neutral from Buy at Chardan
TipRanks · 5d ago
More
About MCRB
More
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Recently
Symbol
Price
%Change

Webull offers Seres Therapeutics Inc stock information, including NASDAQ: MCRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MCRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MCRB stock methods without spending real money on the virtual paper trading platform.